Programas de capacitación para epidemiología de campo.

Same author

The cartography of KRAS inhibitor resistance in colorectal cancer.

Cancer cell·2026

Same author

First Reported Human Cases of Urolithin A Renal Calculi.

Kidney international reports·2026

Same author

Erratum: Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Residual Stone Volume Predicts Health Care Consumption and Stone Events: Analysis of Two-Year Results of the ASPIRE Study.

Journal of endourology·2026

Same author

Commentary: Design science research as a pathway to strengthening evidence within the nursing intervention classification.

Journal of research in nursing : JRN·2026

Same author

MAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance.

Nature·2025

Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026

Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026

Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026

Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026

Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026

Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026

Videos de Experimentos Relacionados

Programas de capacitación para epidemiología de campo.

Videos de Conceptos Relacionados

The cartography of KRAS inhibitor resistance in colorectal cancer.

First Reported Human Cases of Urolithin A Renal Calculi.

Erratum: Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors.

Residual Stone Volume Predicts Health Care Consumption and Stone Events: Analysis of Two-Year Results of the ASPIRE Study.

Commentary: Design science research as a pathway to strengthening evidence within the nursing intervention classification.

MAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance.

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Videos de Experimentos Relacionados

Programas de capacitación para epidemiología de campo.

Videos de Conceptos Relacionados

Artículos Relacionados

The cartography of KRAS inhibitor resistance in colorectal cancer.

First Reported Human Cases of Urolithin A Renal Calculi.

Erratum: Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors.

Residual Stone Volume Predicts Health Care Consumption and Stone Events: Analysis of Two-Year Results of the ASPIRE Study.

Commentary: Design science research as a pathway to strengthening evidence within the nursing intervention classification.

MAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance.

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.